🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 16 Manchester 9 Leeds 8 Cardiff 8 Newcastle upon Tyne 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London16 Manchester9 Leeds8 Cardiff8 Newcastle upon Tyne6
All 30 cities
Target enrolment
to
16 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Cambridge, London, Sutton
2026-04-22
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
BioNTech SE
Phase 1/2
482
London, Manchester, Sutton
2025-07-18
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
BioNTech SE
Phase 1/2
594
Bristol, Leeds, Liverpool, London, Manchester, Preston
2025-05-02
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
BioNTech SE
Phase 2
60
Cardiff, Leeds, London, Manchester
2025-03-03
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
BioNTech SE
Phase 2/3
1,580
Bath, Brighton, Cardiff, Chelsea, Cottingham, Glasgow, Liverpool, London
2025-01-07
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
Cottingham, Edinburgh, Leeds, London
2024-08-26
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
BioNTech SE
Phase 1
320
Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne
2022-06-17
Active, closed
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.